

METHOD OF THERAPYFIELD OF THE INVENTION

Numerous diseases have been linked to the production of regulator cells. The 5 present invention relates to the observation that the immune system is cycling in these diseases. Based on these observations, the present invention provides methods for treating diseases such as cancer and a HIV infection. The present invention also relates to methods of determining when a therapy to treat a disease characterized by the production of regulator cells should be administered to a patient.

10

BACKGROUND OF THE INVENTION

In the past, attempts have been made to trigger the immune system to mount an efficient response against malignant cells. Despite significant and promising progress, such a response has yet to be fully attained and many immune based therapies have 15 proved disappointing.

Numerous studies using *in vitro* cellular assays demonstrate that cytotoxic lymphocytes have the ability to kill tumour cells. Why this immune based destruction does not effectively control tumour growth *in vivo* is a conundrum. The cancer patient also has increased concentration of circulating immune complexes, indicating the 20 immune system is active, particularly against certain tumour antigens. The level of these immune complexes can increase with disease progression (Horvath *et al*, 1982; Aziz *et al*, 1998).

Regulatory cells (also referred to in the art as suppressor cells) have been implicated in a subjects immune response to cancer (North and Awwad, 1990; WO 25 03/068257). As most cancer antigens are actually produced by the patient they are considered as "self" by the immune system. Upon the presence, and/or increased quantity, of tumour antigen the hosts immune system mounts a response characterized by the production of effector cells which target cells producing the tumour antigen. However, in many instances these effector cells are recognized by the immune system 30 as targeting the hosts own cells, and hence a population of regulator cells are produced to down-regulate the effector cell population. Thus, the production of these regulator cells limits the ability of the immune system to effectively remove cancer cells.

More recently, regulator cells have been shown to be involved in a subjects immune response to a viral infection. WO 02/13828 describes the production of 35 regulator cells during retroviral infection, and methods of treating such infections by down-regulating the regulator cell population whilst maintaining the effector cell

population. Furthermore, Peterson *et al* (2002) observed that a population of CD4+ regulator cells were suppressing the ability of CD8+ effector cells to control Friend murine retrovirus infections in mice.

Measurements of certain acute-phase protein plasma concentrations can be of diagnostic or prognostic value under specific clinical conditions. The best known acute-phase protein is C-reactive protein (CRP). CRP is a plasma protein that rises in the blood with the inflammation from certain conditions. The level of CRP in blood plasma can rise as high as 1000-fold with inflammation. Conditions that commonly lead to marked changes in CRP include bacterial and viral infection, trauma, surgery, burns, inflammatory conditions, coronary and vascular disease and advanced cancer.

Most acute phase proteins are synthesized by hepatocytes, some are produced by other cell types, including monocytes, endothelial cells, fibroblasts and adipocytes. Acute phase proteins include serum amyloid A (SAA), CRP and serum amyloid P component (SAP).

The immediate responsiveness of CRP and SAA to stimuli, together with their wide concentration range and ease of automated measurement, have led to plasma CRP and SAA levels being used to monitor accurately the severity of inflammation and the efficacy of disease management during certain disease conditions.

WO 03/070270 describes the use of acute phase inflammatory markers in regimes for the effective treatment of HIV. These methods rely on at least partially "resetting" the immune system by a treatment such as HAART followed by the analysis of acute phase inflammatory proteins as markers for effector/regulator cell expansion. The emergence of acute phase inflammatory proteins appears to be linked to effector cell expansion, which occurs before regulator cell expansion, and thus the patient can be treated with a suitable agent which allows the effector cell population to be maintained whilst destroying, preventing the production of, or reducing the activity of, regulator cells. In essence, upon withdrawal of HAART treatment it was considered that the patient's immune system would treat the re-emerging HIV particles as a new infection, and hence a new population of effector cells would be produced.

Similar to WO 03/070270, WO 03/068257 relates to at least partially resetting the immune system, however, in this instance in the context of the treatment of cancer. Again, the treatment is focussed on the initial re-emergence of effector cells following a reduction in tumour load through techniques such as surgery or the administration of anti-proliferative drugs.

Neither WO 02/13828, WO 03/070270 or WO 03/068257 appreciate that the immune response is cycling in a cancer or HIV patient regardless of the administration

of treatment for these diseases. The present invention is based on the realization of this cycling, and thus provides methods for the treatment of diseases linked to regulator cell production or activity.

## 5 SUMMARY OF THE INVENTION

The present inventor has surprisingly found that the immune system is cycling during disease states characterized by the presence of regulator cells. This cycling occurs on a regular basis of approximately 14 to 15 days in humans.

Whilst not wishing to be limited by theory, it appears that effector cell expansion against a target antigen is followed by the expansion of regulator cells directed against the effectors. Upon control of the effector cells by the regulator cells the numbers and/or activity of both types of cells decrease, which in turn is followed by the same cycle due to the continuous presence or incomplete removal of antigen which results in an oscillating persistent, but ineffective, immune response against the, for example, tumour or virus.

Knowledge of this cycle can be used to treat diseases where it is known that the emergence of regulator cells is detrimental to the patient. Examples of such diseases include cancer and persistent infections such as by the human immunodeficiency virus. More specifically, treatment of a patient can be timed such that effector cell numbers against a cellular or viral antigen are maximized whilst regulator cell numbers are reduced or abolished.

In fact, the present inventor has noted that the treatment of a wide variety of cancers with anti-cancer drugs results, on average, in a complete response rate in the range of 6.5 to 7%. This range of 6.5 to 7% is consistent with an about 14 to 15 day cycle of effector cell expansion followed by regulator cell expansion. More specifically, when not taking into consideration the cycling of effector and regulator cells, a medical practitioner has an approximate 1 in 14.5 chance (6.8%) of administering an anti-proliferative drug at a time where effector cells numbers are high but regulator cell numbers have only begun to expand and hence are vulnerable to treatments which target dividing cells. This leaves high numbers of effector cells which target the cancer cells, resulting in a complete response to the therapy.

Accordingly, in a first aspect the present invention provides a method for determining when an agent should be administered to a patient suffering from a disease characterized by the production of regulator cells, the method comprising monitoring the patient, or samples obtained therefrom, for at least one of: a) effector cell numbers

and/or activity, b) regulator cell numbers and/or activity, c) a molecule associated with the disease, and/or d) an immune system marker.

In another aspect, the present invention provides a method of treating a disease characterized by the production of regulator cells, the method comprising;

5        i) monitoring a patient suffering from the disease for at least one of:

- a) number and/or activity of regulator cells,
- b) number and/or activity of effector cells,
- c) a molecule associated with the disease, and/or
- d) an immune system marker, and

10      ii) exposing the patient to an agent to treat the disease,

wherein the timing of administration of the agent is selected such that the activity of effector cells is not significantly reduced.

Preferably, the disease characterized by the production of regulator cells is selected from, but not limited to, cancer and an infection.

15      The infection can be caused by any type of infectious agent such as, but not limited to, a virus, bacteria, protozoa, nematode, prion, or fungus. Preferably, the infectious agent causes chronic persistent infection characterized by the patient immune system not being able to eliminate the infectious agent. Examples of infectious agents which cause chronic persistent infection are viruses such as HIV, the Hepatitis B virus  
20 and the Hepatitis C virus.

Whilst not wishing to be limited by theory, it appears that as antigen load, for example from increased tumour growth or viral replication, increases following regulator cell activity the patient's immune system responds in a manner similar to a first time exposure to the antigen. This immune response includes the production of:  
25 acute phase inflammatory markers such as serum amyloid A and c-reactive protein.

An appropriate time to administer the agent is between when the levels of acute phase inflammatory marker have peaked and before the marker begins to rise in the next cycle. Accordingly, a particularly preferred immune system marker is an acute phase inflammatory marker. More preferably, the acute phase inflammatory marker is  
30 selected from, but not limited to, the group consisting of serum amyloid A, serum amyloid P and c-reactive protein.

Preferably, the immune system marker reflects the number and/or activity of regulator cells, and/or the number and/or activity of effector cells.

In one embodiment, the patient is monitored for an increase in the number  
35 and/or activity of regulator cells by the analysis of CD4+CD8- T cell levels. With

regard to this embodiment, it is preferred that the agent is administered about when CD4+CD8- T cells are detected.

In another embodiment, the patient is monitored for an increase in the number and/or activity of effector cells by the analysis of CD8+CD4- T cell levels. With 5 regard to this embodiment, it is preferred that the agent is administered approximately when CD8+CD4- T cell numbers have peaked.

In another embodiment, the molecule associated with the disease is an antigen produced by a cancer cell or an infectious agent. In this embodiment, the agent is administered approximately when levels of the molecule associated with the disease 10 begin to decrease.

In a further embodiment, the disease is cancer and the patient is monitored for fluctuations in the levels of tumour antigen(s). With regard to this embodiment, it is preferred that the agent is administered approximately when levels of tumour antigen begin to decrease.

15 In yet a further embodiment, the disease is caused by an infectious agent and the patient is monitored for fluctuations in the levels of antigen(s) produced by the infectious agent. With regard to this embodiment, it is preferred that the agent is administered approximately when levels of antigen, or infectious organisms or viruses (viral load), begin to decrease.

20 In another embodiment, the immune system marker is body temperature. With respect to this embodiment, it is preferred that the agent is administered when body temperature has peaked and before body temperature begins to rise in the next cycle.

As outlined herein, the present inventor has noted that fluctuations in numerous factors indicate that the immune system is cycling in patients suffering from a disease 25 characterized by the production of regulator cells. These factors include acute phase inflammatory markers, viral antigens, cancer antigens and body temperature. These factors are linked, directly or indirectly, to the general state of the immune system including, but not necessarily limited to, effector cell production and/or activity, regulator cell production and/or activity, and/or B cell production and/or activity.

30 It will be appreciated by the skilled person that diseases such as cancer and AIDS have a complex effect on the patient. Furthermore, natural variations between individuals linked to factors such as their genotype, nutrition, fitness, previous and current disease status, all influence how a given individual responds to a disease state. Thus, whilst in most cases the cycle will be about 14 to 15 days, in some individuals 35 this may be slightly shorter or longer. In addition, like the menstrual cycle, the length of the cycle may vary slightly within an individual due to natural variation and/or

environmental factors. Thus, individual variation may at least be encountered with regard to, for example, i) the length of the cycle, ii) the absolute numbers of effector or regulator cells during the cycle, or iii) the levels of acute phase inflammatory markers during the cycle. Such variation may be exaggerated in patients with advanced cancer  
5 or infection, where the patient's immune system has been challenged for a considerable length of time.

As result, it will most likely be desirable to monitor the patient for a sufficient length of time to ensure that the dynamics of the immune system cycling within a particular patient is understood. Preferably, the patient is monitored for a period of at  
10 least 7 days, more preferably at least 14 days, more preferably at least 21 days, more preferably at least 28 days, more preferably at least 35 days, more preferably at least 42 days, and even more preferably at least 49 days.

Another complicating factor is that at least the levels of some acute phase inflammatory markers have been found to cycle about every 7 days (about half the  
15 length of a "full" immune system cycle). Thus, it appears that relying on these types of markers will improve the chance of successful treatment from about 6.8% (based on random administration of the agent) to about 50% (based on choosing the correct administration time by randomly choosing which of the peaks is linked to the appropriate time to target regulator cells). Whilst this is an improvement on current  
20 techniques, it is preferred that such markers are monitored in conjunction with other factors (for example, a molecule associated with the disease, regulator cells and/or effector cells) to optimize the chance of selecting the appropriate time to administer the agent.

Thus, in another embodiment, the patient is monitored for an acute phase  
25 inflammatory marker, and a molecule associated with the disease. With regard to this embodiment, the agent is administered between when the levels of the acute phase inflammatory marker have peaked and before the marker begins to rise in the next cycle, and when levels of the molecule associated with the disease begin to decrease or would have been predicted to begin to decrease based upon previous analysis of the  
30 molecule.

In general, it is preferred that numerous factors are monitored at the same time. This is because, due to the factors describe above, it is unlikely that each factor will have a perfect cycle profile within a 14/15 day period, particularly over a number of cycles, to routinely provide a clear indication of the appropriate time to administer the  
35 agent. Whilst the analysis of numerous factors of a long period may be costly, and may be of at least some inconvenience to the patient, diseases such as cancer and AIDS are

life threatening. Hence it is worthwhile understanding as much as possible regarding immune system cycling in a given patient before the patient is treated.

In addition, although the analysis of different factors cycling in some patients may result in complex profiles, given the guidance provided herein it is well within the  
5 skill of the medical practitioner to analyse the monitoring data to determine the optimal time to administer the agent. An Example of the careful analysis of multiple factors to determine the appropriate time to effectively treat a disease characterized by the production of regulator cells is provided herein.

A further complicating factor will be if the patient has recently acquired a  
10 disease or trauma unrelated to that being treated. For example, a patient being treated for a HIV infection may also contract the common flu virus. The presence of the flu virus will result in, for example, an increase in acute phase inflammatory markers independent of the cycling of these markers which is occurring due to the HIV infection. Other diseases which may cause complications in monitoring  
15 effector/regulator cell cycling for use in the methods of the present invention include, rheumatoid arthritis, ulcers and chronic gum disease. Accordingly, it is desirable to monitor the patient for any factors which may result in elevated levels of, for example, acute phase inflammatory markers to ensure that the factor being monitored truly reflects effector/regulator cell cycling resulting from the disease being treated.

20 Furthermore, it is preferred that the patient is monitored as frequently as possible to ensure immune system cycling within a given patient is suitably characterized. Naturally this will ensure that the agent is administered at the appropriate time and that any small variations in, for example, effector/regulator cell numbers or activity, or markers thereof, is not misinterpreted. Preferably, the patient is  
25 monitored at least every 3 days, more preferably at least every 2 days, and most preferably at least every day. Monitoring may occur more frequently, for instance every 12 hours, when the cycling is reaching a stage where it is likely that the timing would be appropriate to administer the agent.

30 Preferably, the agent inhibits the production of, limits the function of, and/or destroys, regulator cells. More preferably, the agent is selected from the group consisting of anti-cancer drugs such as anti-proliferative drugs, radiation, dsRNA and antibodies which inhibit the production and/or activity of regulator cells. Preferably, the anti-proliferative drug is selected from the group consisting of, but not limited to, taxol, vincristine, vinblastine and anhydro vinblastine.

35 With regard to cancer, in contrast to typical anti-cancer drug therapy which is administered to target tumour cells, the method of treatment described herein actually

targets regulator cells. This leaves suitable numbers of effector cells to produce the desired therapeutic effect.

Examples of preferred antibodies include, but are not limited to, anti-CD4+, anti-CTLA-4 (cytotoxic lymphocyte-associated antigen-4), anti-GITR (glucocorticoid-induced tumour necrosis factor receptor), anti-CD28 and anti-CD25.

Preferably, the patient has not been exposed to a treatment for the disease for at least 14 days, more preferably at least 21 days, and even more preferably at least 28 days.

The present inventor has also determined that treatment for a disease characterized by the production of regulator cells can be enhanced (or the chances of successful treatment can be increased) when the vaccine is administered at the appropriate time. In these instances, the vaccine boosts the innate immune response against the disease. This will most likely be a result of increased numbers and/or activity of effector cells. Although theoretically regulator cells will still ultimately be produced, the boosting of the immune system allows the patient to suitably control the disease before the emergence of the regulator cells. This scenario would explain why previous studies have shown that anti-HIV and anti-tumour vaccines are only successful in a small number of patients. More specifically, there is only a small chance the vaccine will be administered at the same time the innate immune response to the disease is occurring. Other times of administration in the prior art occur when there are high numbers and/or activity of regulators cells, or at times which uncouple the natural cycling of the immune system.

Thus, in another aspect the present invention provides a method for determining when a vaccine should be administered to a patient suffering from a disease characterized by the production of regulator cells, the method comprising monitoring the patient, or samples obtained therefrom, for at least one of: a) effector cell numbers and/or activity, b) regulator cell numbers and/or activity, c) a molecule associated with the disease, and/or d) an immune system marker.

In a further aspect, the present invention provides a method of treating a disease characterized by the production of regulator cells, the method comprising;

- i) monitoring a patient suffering from the disease for at least one of:
  - a) number and/or activity of regulator cells,
  - b) number and/or activity of effector cells,
  - c) a molecule associated with the disease, and/or
  - d) an immune system marker, and
- ii) exposing the patient to an vaccine to treat the disease,

wherein the timing of administration of the vaccine is selected such that the activity of effector cells is not significantly reduced.

In one embodiment, the vaccine is administered about when the levels of effector cells are increasing.

5 In another embodiment, the vaccine is administered about when the levels of a molecule associated with the disease begin to decrease.

In a further embodiment, the vaccine is administered about when the levels of an acute phase inflammatory marker begin to increase. As outlined above, at least some acute phase inflammatory markers have been found to be cycling over about a 10 seven day period where only every second peak of acute phase inflammatory marker levels is associated with effector cell numbers. Thus, in this embodiment, the monitoring will most likely need to be combined with the analysis of other factors described herein.

The observation that the immune system is cycling during disease states 15 characterized by the presence of regulator cells can also be used as an indicator of the presence of such a disease. These diagnosis procedures would be particularly useful for analysing a patient for the recurrence of the disease state (such as a tumour) following treatment, or for analysing a patient determined to be susceptible to the disease (such as in cases where the subject has previously been identified as possessing 20 a cancer susceptibility gene) for the emergence of the disease.

Thus, in a further aspect the present invention provides a method of diagnosing a disease characterized by the production of regulator cells, the method comprising monitoring the patient, or samples obtained therefrom, for at least one of: a) effector cell numbers and/or activity, b) regulator cell numbers and/or activity, c) a molecule 25 associated with the disease, and/or d) an immune system marker, wherein cycling of any one of a) to d) indicates the disease may be present.

Naturally, as outlined above, the patient will need to be analysed for other disease states, such as minor infections such as influenza etc, to ensure that any cycling observed (especially when analysing acute phase inflammatory markers) is directly 30 linked to a disease characterized by the production of regulator cells.

Whilst ideally the monitoring should continue indefinitely, this will most likely not be practical in a majority of situations. Thus, the diagnosis procedure can be performed on an intermittent basis based on assessed risk of the disease state emerging or re-emerging. As the skilled addressee will appreciate from the discussions herein, 35 the term "intermittent basis" means that the method will require a suitable number of samples be analysed over a period of time to determine if immune cycling is occurring

(for example samples obtained at least every 3 days for a period of about 14 days), however, if the test is negative this procedure may not need to be repeated (for example) for another year.

In another aspect, the present invention provides for the use of an assay which  
5 detects an immune system marker for determining when an agent or vaccine should be administered to a patient suffering from a disease characterized by the production of regulator cells.

Preferably, the marker is an acute phase inflammatory marker. More preferably, the marker is a positive acute phase inflammatory marker. Even more preferably, the  
10 marker is selected from the group consisting of, but not limited to, serum amyloid A and c-reactive protein.

In another aspect, the present invention provides for the use of an assay which detects effector cell numbers and/or activity for determining when an agent or vaccine should be administered to a patient suffering from a disease characterized by the  
15 production of regulator cells.

Preferably, the assay detects the number of CD8+CD4- T cells.

In another aspect, the present invention provides for the use of an assay which detects regulator cell numbers and/or activity for determining when an agent or vaccine should be administered to a patient suffering from a disease characterized by the  
20 production of regulator cells.

Preferably, the assay detects the number of CD4+CD8- T cells.

In another aspect, the present invention provides for the use of an assay which detects a molecule associated with a disease characterized by the production of regulator cells for determining when an agent or vaccine should be administered to treat  
25 the disease.

Preferably, the assay detects an antigen produced by a cancer cell or an infectious agent.

Preferably, the patient has not been exposed to a treatment for the disease for at least 14 days, more preferably at least 21 days, and even more preferably at least 28  
30 days.

In a further aspect, the present invention provides for the use of an agent for the manufacture of a medicament for administering to a patient suffering from a disease characterized by the production of regulator cells, wherein the agent will be administered at a time selected such that the activity of effector cells is not significantly reduced, and wherein the patient has not been exposed to a treatment for the disease for  
35 at least 14 days.

Preferably, the agent inhibits the production of, limits the function of, and/or destroys, regulator cells.

As would be readily appreciated by those skilled in the art, the methods of the present invention may be repeated to provide a more complete treatment.

5 Preferably, the patient is a mammal. More preferably, the mammal is a human.

In a further aspect, the present invention provides a kit for determining when an agent or vaccine should be administered to a patient suffering from a disease characterized by the production of regulator cells, the kit comprising at least one reagent for monitoring the patient, or samples obtained therefrom, for at least one of: a) 10 effector cell numbers and/or activity, b) regulator cell numbers and/or activity, c) a molecule associated with the disease, and/or d) an immune system marker.

Preferably, the kit comprises written instructions for performing a method of the invention including reference to the preferred number of samples to be analysed, and the timing between sample analysis.

15 As will be apparent, preferred features and characteristics of one aspect of the invention are applicable to many other aspects of the invention.

Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of 20 any other element, integer or step, or group of elements, integers or steps.

The invention is hereinafter described by way of the following non-limiting Examples and with reference to the accompanying figures.

#### **BRIEF DESCRIPTION OF THE ACCOMPANYING DRAWINGS**

25 Figure 1. A) C-reactive protein and tumour marker CA125 levels over a 14 day period in a patient with ovarian cancer. B) Serum amyloid A levels in the same patient over the same period (C-reactive protein levels from A) duplicated).

Figure 2. C-reactive protein levels in response to taking a first human HIV patient off 30 HAART treatment.

Figure 3. Viral load and CRP fluctuations in a second HIV patient following the completion of HAART.

35 Figure 4. CRP and C4 fluctuations in Mrs OM over 32 days shows a distinct periodicity with an approximate repeating 7 / 14 day oscillation. Measurements were taken every

Monday, Wednesday and Friday. In this case the C4 oscillation is more regular. Note the rising trend in both parameters over the 32 day period.

Figure 5. Serum Complement factors C4 and C3 fluctuations in Mrs OM over 32 days  
5 show a near synchronous and regular periodicity of approximately 7/14 days. Note the rising trend in both parameters over the 32 day period.

Figure 6. Serum Complement Factor C4 fluctuations and rising CA125 levels with advancing disease in Mrs OM. Note the rising trend in both parameters over the 32 day  
10 period.

Figure 7. C- Reactive Protein versus Time in Mrs OM, (days) Monitoring and Therapeutic events, 28<sup>th</sup> May 2004 (day 1) – 9<sup>th</sup> August 2004 (day 74). CRP monitoring began on the 28<sup>th</sup> of May (day 1) and climbed steadily with advancing  
15 disease. The approx 14 day immune response oscillation was derived from the combined interpretation of serum CRP, C4 & CA125 collected data (see also Figure 4).  
Key:

- A = Radiotherapy begins, day 38, = 5<sup>th</sup> July 2004.
- B = Predicted CRP peak, day 46,47 & 48, = 13<sup>th</sup>,14<sup>th</sup>,15<sup>th</sup>, July 2004.
- 20 C = Timing of first chemotherapy application, day 49, 16<sup>th</sup> July 2004.
- D = Predicted CRP peak, day 63 & 64, = 28<sup>th</sup>, 29<sup>th</sup> July 2004. Radiotherapy stops.
- E = Timing of 2<sup>nd</sup> chemotherapy application, day 65, = 30<sup>th</sup> July 2004.
- F = Fever, day 66, = 31st July2004, Haemorrhage from Tumour, day 67, = 1<sup>st</sup> August 2004.
- 25 G = CRP drops to 62.7mg/l, day 69, = 4<sup>th</sup> August 2004.
- H = Endoscopy reporting no evidence of tumour, day 74, = 9<sup>th</sup> August 2004.

Figure 8. C- Reactive Protein and Serum Amyloid A versus time in Mrs FO.

30 Figure 9. C- Serum Amyloid A and IL-2 versus time in Mrs FO.

Figure 10. Serum Amyloid A and cancer marker CA125 versus time in Mrs FO.

Figure 11. C- Reactive Protein and C3 versus time in Mrs FO.

35

Figure 12. C- Reactive Protein versus time in Mr GA.

**DETAILED DESCRIPTION OF THE INVENTION****Definitions**

As used herein the terms "treating", "treat" or "treatment" include administering 5 a therapeutically effective amount of an agent sufficient to reduce or eliminate at least one symptom of the disease.

As used herein, the term "tumour load" generally refers to the number of cancerous cells in a subject at any given time. Measuring the level of tumor antigen in the subject can be considered as an indication of tumour load.

10 As used herein, the term "viral load" generally refers to the number of viral particles in a subject at any given time. Measuring the level of viral antigen in the subject can be considered as an indication of viral load.

"Regulator cells" include, but are not necessarily limited to, a subpopulation of CD4+ T cells. Such cells may also be referred to in the art as "suppressor cells". 15 Regulator cells may either act directly on effector cells or may assert their affects upon effector cells through other mechanisms.

CD4+ cells express the marker known in the art as CD4. Typically, the term "CD4+ T cells" as used herein does not refer to cells which also express CD8. However, this term can include T cells which also express other antigenic markers such 20 as CD25.

"Effector cells" include, but are not necessarily limited to, the T cell population known as CD8+ cells.

As used herein, the term "limits the function of, and/or destroys" when referring to the exposure of the "regulator cells" to the agent means that the number, and/or 25 activity, of regulator cells is down-regulated by the agent. Most preferably, the number, and/or activity, of regulator cells is completely eradicated by the agent.

As used herein the term "disease characterized by the production of regulator cells" refers to any condition wherein the number or activity of regulator cells plays a role in prolonging the disease state. Examples of such disease include, but are not 30 limited to, cancer and infections.

The term "immune system marker" generally refers to any molecule or factor which provides an indication of the state and/or activity of the immune system. These markers may be directly linked to the activity and/or production of regulator and/or effector cells, and/or may provide a more general indication of the overall response of 35 the immune system to an antigen. Examples of a suitable immune system marker include acute phase inflammatory markers such as c-reactive protein and serum

amyloid A. Another example of an immune system marker are indicators of cellular destruction such as, but not limited to, cholesterol and beta -2-microglobulin in serum. Cholesterol and beta -2-microglobulin are integral components of cellular membranes. In particular, beta -2-microglobulin is the accessory molecule to the Major Histocompatibility Class I or MHC- I receptor. Consequently, with the cycling of the anti-disease immune response together with target cell destruction, the serum levels in cancer patients of these two molecules is often elevated. Thus, oscillations in indicators of cellular destruction, such as cholesterol and beta -2-microglobulin, may also prove useful in determining the beginning or end of the immune response cycle.

Naturally, upon the present discovery of the immune system cycling in a disease characterized by the production of regulator cells, the skilled addressee could readily identify further markers useful in the methods of the invention.

As used herein, the term "a molecule associated with the disease" refers to any molecule which is linked to the disease state. In a preferred embodiment, the marker is a protein. Such protein markers are well known in the art. Examples of suitable tumour antigen markers are described herein. Suitable markers for, if not all, infectious diseases are also well known, for example the gag or env proteins of HIV.

As used herein the term "chronic persistent infection" refers to the presence of an infectious agent in the patient which is not readily controlled by the patient's immune system or available therapies. Examples include, but are not limited to, infections with *Mycobacterium tuberculosis* (which causes tuberculosis), HIV, the Hepatitis B virus or the Hepatitis C virus. To be classified as a "chronic persistent infection" it is preferred that the patient has at least had the infection for 3 months, more preferably at least 6 months.

For the purposes of this invention, the term "antibody", unless specified to the contrary, includes fragments of whole antibodies which retain their binding activity for a target analyte. Such fragments include Fv, F(ab') and F(ab')<sub>2</sub> fragments, as well as single chain antibodies (scFv). Furthermore, the antibodies and fragments thereof may be humanised antibodies, for example as described in EP-A-239400.

As is known in the art, a cancer is generally considered as uncontrolled cell growth. The methods of the present invention can be used to treat any cancer including, but not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia. More particular examples of such cancers include breast cancer, prostate cancer, colon cancer, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, liver cancer, bladder cancer, hepatoma, colorectal cancer, uterine cervical

cancer, endometrial carcinoma, salivary gland carcinoma, mesothelioma, kidney cancer, vulval cancer, thyroid cancer, hepatic carcinoma, skin cancer, melanoma, brain cancer, neuroblastoma, myeloma, various types of head and neck cancer, acute lymphoblastic leukemia, acute myeloid leukemia, Ewing sarcoma and peripheral 5 neuroepithelioma.

The "sample" refers to a material suspected of containing regulator cells, effectors cells, immune system markers and/or a molecule associated with the disease. The sample can be used as obtained directly from the source or following at least one step of (partial) purification. The sample can be prepared in any convenient medium 10 which does not interfere with the method of the invention. Typically, the sample is an aqueous solution or biological fluid as described in more detail below. The sample can be derived from any source, such as a physiological fluid, including blood, serum, plasma, saliva, sputum, ocular lens fluid, sweat, faeces, urine, milk, ascites fluid, mucous, synovial fluid, peritoneal fluid, transdermal exudates, pharyngeal exudates, 15 bronchoalveolar lavage, tracheal aspirations, cerebrospinal fluid, semen, cervical mucus, vaginal or urethral secretions, amniotic fluid, and the like. Preferably, the sample is blood or a fraction thereof. Pretreatment may involve, for example, preparing plasma from blood, diluting viscous fluids, and the like. Methods of treatment can involve filtration, distillation, separation, concentration, inactivation of 20 interfering components, and the addition of reagents. The selection and pretreatment of biological samples prior to testing is well known in the art and need not be described further.

Unless otherwise indicated, the recombinant DNA and immunological techniques utilized in the present invention are standard procedures, well known to 25 those skilled in the art. Such techniques are described and explained throughout the literature in sources such as, J. Perbal, A Practical Guide to Molecular Cloning, John Wiley and Sons (1984), J. Sambrook *et al*, Molecular Cloning: A Laboratory Manual, Cold Spring Harbour Laboratory Press (1989), T.A. Brown (editor), Essential Molecular Biology: A Practical Approach, Volumes 1 and 2, IRL Press (1991), D.M. 30 Glover and B.D. Hames (editors), DNA Cloning: A Practical Approach, Volumes 1-4, IRL Press (1995 and 1996), and F.M. Ausubel *et al* (editors), Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience (1988, including all updates until present), Ed Harlow and David Lane (editors) Antibodies: A Laboratory Manual, Cold Spring Harbour Laboratory, (1988), and J.E. Coligan *et al* 35 (editors) Current Protocols in Immunology, John Wiley & Sons (including all updates until present), and are incorporated herein by reference.

Acute Phase Inflammatory Markers

Some acute phase inflammatory markers initially increase during an immune response (referred to hereinafter as positive acute phase inflammatory markers) whilst others initially decrease during an immune response (referred to hereinafter as negative acute phase inflammatory markers). Acute phase inflammatory markers are also referred to in the art as acute phase reactants or acute phase proteins. The skilled addressee will be aware of the many assays which can be used to monitor acute phase inflammatory markers.

Examples of positive acute phase inflammatory markers include, but are not limited to, c-reactive protein, serum amyloid A, serum amyloid P component, complement proteins such C2, C3, C4, C5, C9, B, C1 inhibitor and C4 binding protein, fibrinogen, von Willebrand factor,  $\alpha$ 1-antitrypsin,  $\alpha$ 1-antichymotrypsin,  $\alpha$ 2-antiplasmin, heparin cofactor II, plasminogen activator inhibitor I, haptoglobin, haemopexin, ceruloplasmin, manganese superoxide dismutase,  $\alpha$ 1-acid glycoprotein, haeme oxygenase, mannose-binding protein, leukocyte protein I, lipoprotein (a), lipopolysaccharide-binding protein, and interleukins such as IL-1, IL-2, IL-6, IL-10 and receptors thereof.

Example of negative acute phase inflammatory markers include, but are not limited to, albumin, pre-albumin, transferrin, apoAI, apoAII,  $\alpha$ 2 HS glycoprotein, inter- $\alpha$ -trypsin inhibitor, histidine-rich glycoprotein.

Serum amyloid A (SAA) was discovered as a plasma component that shares antigenicity with amyloid AA, the chief fibrillar component in reactive AA amyloid deposits. SAA has been shown to be an acute phase reactant whose level in blood is elevated to 1000-fold or higher as part of the body's responses to various injuries including trauma, infection and inflammation.

SAA levels can be determined as known in the art, see for example Weinstein *et al* (1984), Liuzzo *et al* (1994), O'Hara *et al* (2000), Kimura *et al* (2001) and O'Hanlon *et al* (2002).

C-reactive protein (CRP) is an important positive acute phase response protein, and its concentration in serum may increase as much as 1,000-fold during the acute phase response. CRP is a pentamer consisting of five identical subunits, each having a molecular weight of about 23,500.

C-reactive protein levels can be determined using techniques known in the art, these include, but are not limited to, those disclosed in Senju *et al* (1983), Weinstein *et*

*al* (1984), Price *et al* (1987), Liuzzo *et al* (1994), Eda *et al* (1998), Kimura *et al* (2001) and O'Hanlon *et al* (2002).

The complement proteins are a group of at least 20 immunologically distinct components. They normally circulate in the blood in an inactive form. They are able to 5 interact sequentially with antigen – antibody complexes, with each other and with cell membranes in a complex but adaptable way to destroy viruses and bacteria and pathologically, even the hosts own cells. Abnormal serum levels of complement proteins may be due to either inherited or acquired diseases. At least circulating levels of C3 and C4 reflect a balance between complement consumption due to immune 10 complex formation and increased synthesis due to acute phase response. Methods of measuring complement protein levels are well known in the art.

Levels of different interleukins can also be determined using procedures known in the art such as using the ProteoPlex<sup>TM</sup> cytokine assay kit (EMD Biosciences Inc., CA, USA).

15

#### Agents

The agent can be any factor or treatment useful in treating a disease characterized by the production of regulator cells. Preferably, the agent selectively or non-selectively results in the destruction, the inhibition of the production, or reduction 20 of activity, of regulator cells. For example, a CD4+ specific antibody could be used to specifically target CD4+ T cells. However, in some instances a non-selective agent could be used, such as an anti-proliferative drug or radiation, both of which destroy dividing cells. In particular, as with other cell types, regulator cells are particularly vulnerable to destruction by anti-mitotic (anti-proliferative) drugs or spindle poisons 25 (e.g. Vinblastine or paclitaxel) when dividing and specifically in mitosis.

The term "anti-proliferative drug" is a term well understood in the art and refers to any compound that destroys dividing cells or inhibits them from undergoing further proliferation. Anti-proliferative drugs include, but are not limited to, mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, hexamethyl-melamine, 30 thiotepa, busulfan, carmustine, lomustine, semustine, streptozocin, dacarbazine, methotrexate, fluorouracil, floxuridine, cytarabine, mercaptopurine, thioguanine, pentostatin, vinblastine, anhydro vinblastine, vincristine, etoposide, teniposide, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicamycin, mitomycin, L-asparaginase, cisplatin, mitoxantrone, hydroxyurea, procarbazine, mitotane, 35 aminoglutethimide, prednisone, hydroxyprogesterone caproate, medroprogesterone acetate, megestrol acetate, diethylstilbestrol, ethinyl estradiol, tamoxifen, testosterone

propionate, radioactive isotopes, ricin A chain, taxol, diphtheria toxin, colchicine and pseudomonas exotoxin A.

The agents are usually administered in the dosage forms that are readily available to the skilled clinician, and are generally administered in their normally prescribed amounts (as for example, the amounts described in the Physician's Desk Reference, 55th Edition, 2001, or the amounts described in the manufacturer's literature for the use of the agent).

In one embodiment, the agent is administered as a single bolus injection. In another embodiment, the agent is administered by infusion. The period of infusion can 10 be, for example, at least 3 hours, at least 12 hours or at least 24 hours.

Recent studies have suggested that CD4+CD25+ T cells play an important role in regulating immune cells directed against self antigens (Salomon *et al*, 2000; Suri-Payer and Cantor, 2001). Furthermore, targeting CD4+CD25+ T cells has been shown to enhance the ability of an animal to control tumour growth (Onizuka *et al*, 1999; 15 Shimizu *et al*, 1999; Sutmuller *et al*, 2001). Accordingly, CD4+CD25+ T cells could be acting as regulator cells as used herein. The activity of CD4+CD25+ T cells can be downregulated by anti-GITR, anti-CD28 and/or anti-CTLA-4 (Read *et al*, 2000; Takahashi *et al*, 2000; Shimizu *et al*, 2002). Thus, these antibodies may be useful as agents for use in the methods of the present invention.

Another example of an agent which can be administered in a method of the 20 invention is dsRNA. dsRNA is used in RNA interference (RNAi) which is a phenomenon where upon introduction into a cell, mRNA homologous to the dsRNA is specifically degraded so that synthesis of gene products is suppressed. Examples of such an agent causing RNAi include, but are not limited to, a sequence having at least 25 about 70% homology to the nucleic acid sequence of a target gene or a sequence hybridizable under stringent conditions, RNA containing a double-stranded portion having a length of at least 10 nucleotides or variants thereof. Examples of target genes include, but are not limited to, a gene required for replication of a regulator cell, a gene required for survival of a cancer cell, or a gene required for growth and/or replication 30 of an infectious agent.

dsRNA having a length of about 20 bases (e.g., representatively about 21 to 23 bases) or less than about 20 bases, which is called siRNA in the art, can be used. Expression of siRNA in cells can suppress expression of a gene targeted by the siRNA. In another embodiment, an agent capable of causing RNAi may have a short hairpin 35 structure having a sticky portion at the 3' terminus (shRNA; short hairpin RNA). As used herein, the term "shRNA" refers to a molecule of about 20 or more base pairs in

which a single-standed RNA partially contains a palindromic base sequence and forms a double-strand structure therein (i.e., a hairpin structure). shRNA can be artificially chemically synthesized. Alternatively, shRNA can be produced by linking sense and antisense strands of a DNA sequence in reverse directions and synthesizing RNA *in vitro* with T7 RNA polymerase using the DNA as a template. The length of the double-stranded portion is not particularly limited, but is preferably about 10 or more nucleotides, and more preferably about 20 or more nucleotides. The 3' protruding end may be preferably DNA, more preferably DNA of at least 2 nucleotides in length, and even more preferably DNA of 2-4 nucleotides in length.

10 An agent capable of causing RNAi useful for the invention may be artificially synthesized (chemically or biochemically) or naturally occurring. There is substantially no difference therebetween in terms of the effect of the present invention. A chemically synthesized agent is preferably purified by liquid chromatography or the like.

15 An agent capable of causing RNAi used in the present invention can also be produced *in vitro*. In this synthesis system, T7 RNA polymerase and T7 promoter can be used to synthesize antisense and sense RNAs from template DNA. These RNAs are annealed and thereafter are introduced into a cell.

dsRNA can be delivered to the patient using any means known in the art.  
20 Examples of methods of delivering dsRNA to a patient are described in, for example, US 20040180357, US 20040203024 and 20040192629.

#### Timing of Exposing the Subject to the Agent

For the investigator who randomly applies a single treatment of anti-proliferative chemotherapy to a cancer patient there is an approximate 1 in 14, to 1 in 15, chance of getting the timing right. A one in fourteen chance equates to a 7% probability of applying the therapy on the correct day, when the regulator cells are vulnerable to inactivation. If this is done, the tumour should regress mediated by immune destruction. More specifically, it is our hypothesis that once the regulators  
25 cells have been removed by therapeutic intervention, the immune response against the tumour or virus can proceed unimpeded, ultimately leading to control of the disease.

Whilst not wishing to be limited by theory, it is believed that the relative number of effector cells expands in response to an antigen before the regulator cells. Accordingly, as used herein, the term "the activity of the effector cells is not  
35 significantly reduced" means that the timing of the administration of the agent is such that the agent exerts a proportionally greater effect against the regulator cells than the

effector cells. It is clearly preferred that the agent is administered at a time when the ratio of effect against the regulator cells to the effect against effector cells is greatest.

As outlined above, the present invention relies on the phenomenon that the immune system is cycling over an approximate 14 to 15 day period in a patient suffering from a disease characterized by the production of regulator cells. In most instances, the time point that the agent is to be administered will need to be empirically determined in subjects at different stages of disease as their immune response kinetics may vary. Other factors such as the general health of the subject and/or the genetic makeup of the subject will also impact upon when is the appropriate time to administer the agent.

As will be appreciated by the skilled addressee, conditions such as cancer and chronic persistent infectious are serious, often life threatening, diseases. Due to many factors, not the least of which is natural variations between individuals, it will be typically be required that a patient be monitored for a reasonable length of time to appreciate the nature of immune cycling in the individual, and for monitoring to analyse a number of factors (such as a combination of acute phase markers and disease antigens), to ultimately determine the most appropriate time to administer the agent to optimise the chances of an effective treatment.

Techniques known in the art can be used to monitor the growing population of effector and/or regulator cells during the "cycle".

Serial blood samples can be collected and quantitatively screened for all CD4+ subsets by FACS analysis. This FACS monitoring will need to be maintained until the regulator cells begin clonally expanding in response to the disease state, whether produced by the tumour or administered to the subject. Other possible assays for monitoring the growing population of regulator cells include lymphocyte proliferation/activation assays and various cytokine level assays (for example an assay for IL-4, IL-6 or IL-10).

Also, serial blood samples can be collected and quantitatively screened for all effector cell activity such as but not limited to CD8+, CRP, SAA and various cytokines. Such effector cell markers will precede the regulator cell markers.

When the disease is cancer another avenue of determining the time point for administering the agent is to monitor the tumour load. It is envisaged that the tumour load decreases due to the activity of the effector cells, however, the subsequent increase in regulator cells would down-regulate the effector cells resulting in a slowing of the tumour load decrease. Accordingly, the agent could be administered approximately prior to the slowing of the decrease in tumour load. Techniques known in the art, for

example RT-PCR or antibody detection, of markers expressed by the tumour, could be used to measure tumour load in these circumstances. Examples of suitable tumour antigen marker assays include, but are not limited to, for AFP (marker for hepatocellular carcinoma and germ-cell tumours), CA 15-3 (marker for numerous cancers including breast cancer), CA 19-9 (marker for numerous cancers including pancreatic cancer and biliary tract tumours), CA 125 (marker for various cancers including ovarian cancer), calcitonin (marker for various tumours including thyroid medullary carcinoma), catecholamines and metabolites (phaeochromoctoma), CEA (marker for various cancers including colorectal cancers and other gastrointestinal cancers), hCG/beta hCG (marker for various cancers including germ-cell tumours and choriocarcinomas), 5HIAA in urine (carcinoid syndrome), PSA (prostate cancer), serotonin (carcinoid syndrome) and thyroglobulin (thyroid carcinoma).

Monitoring may need to be very frequent, for example as often as every few hours, to ensure the correct time point is selected for administration of the agent. 15 Preferably, the monitoring is conducted at least every 48 hours. More preferably, the monitoring is conducted at least every 24 hours.

Optimally, the monitoring is continued to determine the affect of the agent. Insufficient down-regulation, re-emergence of the regulator cells or increases in, for example, tumour load will mean that the method of the present invention should be 20 repeated. Such repeated cycles of treatment may generate immunological memory. It is therefore possible that the present invention, used in repetitive mode, may provide some prophylactic protective effect.

#### Vaccines

25 As outlined above, the inventor has also noted after a survey of the literature that the treatment of a variety of cancers with therapeutic vaccines, on average yielded a complete response rate of approximately 10% (see, for example, Trefzer *et al.*, 2004; Lotem *et al.*, 2004; Smithers *et al.*, 2003; Belli *et al.*, 2002; Berd *et al.*, 2001; Wittig *et al.*, 2001). This implies a window of opportunity of therapeutic application of 1.5 days 30 every 14 days (10%). This is similar and well within the realms of probability of the complete response rates of approximately 7% (1 day in 14) seen in cancer chemotherapy reported herein. Thus a similar mechanism is operating in the vaccine situation whereby the inoculation of a cancer vaccine into the patient at the correct time is sufficient to disturb the regulatory mechanisms/cells allowing the effectors to 35 kill the tumour resulting in a complete response.

Naturally, vaccines used in the present invention will result in an immune response against a disease characterized by the production of regulator cells. Such vaccine will comprise at least one antigen, or a polynucleotide encoding said antigen. The vaccine can be provided as any form known in the art such as, but not limited to, a DNA 5 vaccine, ingestion of a transgenic organism expressing the antigen, or composition comprising the antigen.

As used herein, an "antigen" is any polypeptide sequence that contains an epitope which is capable of producing an immune response against the disease.

Antigens which are capable of raising an immune response against a cancer cell

- 10. are well known in the art. Certain tumour antigens can be recognized and targeted by the immune system. This property may be due to overexpression by the tumour tissue. Some of these antigens can be detected in normal tissue. The tumour antigens targeted by T cells are generally proteins that are processed intracellularly and presented as short peptide fragments bound in the groove of the tumour MHC class I molecule to be
- 15. recognized by CD8<sup>+</sup> cytotoxic T lymphocytes. The mere presence of a tumour antigen is not always sufficient to trigger an immune response. Co-stimulatory molecules such as B7.1 are sometimes required. Once antigen-specific T cells are stimulated, they are capable of recognizing and destroying the tumour. The conditions needed for the activation of antigen-specific T cells are stringent, but are open to genetic manipulation
- 20. of target tumour cells and T cells.

Antigens which can be used to treat infections, such as HIV, are also well known in the art.

The antigen can be provided in any manner known in the art which leads to an immune response. An antigen can be, for example, native, recombinant or synthetic.

- 25. Native antigens can be prepared, for example, by providing cell lysates of a tumour cell.

Vaccines may be prepared from one or more antigens. The preparation of vaccines which contain an antigen is known to one skilled in the art. Typically, such vaccines are prepared as injectables, or orals, either as liquid solutions or suspensions; 30 solid forms suitable for solution in, or suspension in, liquid prior to injection or oral consumption may also be prepared. The preparation may also be emulsified, or the protein encapsulated in liposomes. The antigen is often mixed with carriers/excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable carriers/excipients are, for example, water, saline, dextrose, glycerol, ethanol, 35 or the like and combinations thereof.

In addition, if desired, the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine.

Typically, vaccines comprise an adjuvant. As used herein, the term "adjuvant" means a substance that non-specifically enhances the immune response to an antigen. Examples of adjuvants which may be effective include but are not limited to: N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, referred to as nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1 -2 -dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (CGP 19835A, referred to as MTP-PE), and RIBI, which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPL+TDM+CWS) in a 2% squalene/Tween 80 emulsion. Further examples of adjuvants include aluminum hydroxide, aluminum phosphate, aluminum potassium sulfate (alum), bacterial endotoxin, lipid X, *Corynebacterium parvum* (*Propionobacterium acnes*), *Bordetella pertussis*, polyribonucleotides, sodium alginate, lanolin, lysolecithin, vitamin A, saponin, liposomes, levamisole, DEAE-dextran, blocked copolymers or other synthetic adjuvants. Such adjuvants are available commercially from various sources, for example, Merck Adjuvant 65 (Merck and Company, Inc., Rahway, N.J.) or Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, Michigan).

The proportion of antigen and adjuvant can be varied over a broad range so long as both are present in effective amounts. For example, aluminium hydroxide can be present in an amount of about 0.5% of the vaccine mixture (Al<sub>2</sub>O<sub>3</sub> basis). Conveniently, the vaccines are formulated to contain a final concentration of antigenic polypeptide in the range of from 0.2 to 200 µg/ml, preferably 5 to 50 µg/ml, most preferably 15 µg/ml.

After formulation, the vaccine may be incorporated into a sterile container which is then sealed and stored at a low temperature, for example 4°C, or it may be freeze-dried. Lyophilisation permits long-term storage in a stabilised form.

The vaccines are conventionally administered parenterally, by injection, for example, either subcutaneously or intramuscularly. Additional formulations which are suitable for other modes of administration include suppositories and, in some cases, oral formulations. For suppositories, traditional binders and carriers may include, for example, polyalkylene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably 1% to 2%. Oral formulations include such normally employed excipients as, for example,

pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10% to 95% of active ingredient, preferably 25% to 70%. Where  
5 the vaccine composition is lyophilised, the lyophilised material may be reconstituted prior to administration, e.g. as a suspension. Reconstitution is preferably effected in buffer.

Capsules, tablets and pills for oral administration to a patient may be provided with an enteric coating comprising, for example, Eudragit "S", Eudragit "L", cellulose  
10 acetate, cellulose acetate phthalate or hydroxypropylmethyl cellulose.

DNA vaccination involves the direct *in vivo* introduction of DNA encoding an antigen into tissues of a subject for expression of the antigen by the cells of the subject's tissue. Such vaccines are termed herein "DNA vaccines" or "nucleic acid-based vaccines". DNA vaccines are described in US 5,939,400, US 6,110,898, WO  
15 95/20660 and WO 93/19183, the disclosures of which are hereby incorporated by reference in their entireties.

To date, most DNA vaccines in mammalian systems have relied upon viral promoters derived from cytomegalovirus (CMV). These have had good efficiency in both muscle and skin inoculation in a number of mammalian species. A factor known  
20 to affect the immune response elicited by DNA immunization is the method of DNA delivery, for example, parenteral routes can yield low rates of gene transfer and produce considerable variability of gene expression. High-velocity inoculation of plasmids, using a gene-gun, enhanced the immune responses of mice, presumably because of a greater efficiency of DNA transfection and more effective antigen  
25 presentation by dendritic cells. Vectors containing the nucleic acid-based vaccine of the invention may also be introduced into the desired host by other methods known in the art, e.g., transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, lipofection (lysosome fusion), or a DNA vector transporter.

30 Transgenic plants producing a antigenic polypeptide can be constructed using procedures well known in the art. A number of plant-derived edible vaccines are currently being developed for both animal and human pathogens. Immune responses have also resulted from oral immunization with transgenic plants producing virus-like particles (VLPs), or chimeric plant viruses displaying antigenic epitopes. It has been  
35 suggested that the particulate form of these VLPs or chimeric viruses may result in

greater stability of the antigen in the stomach, effectively increasing the amount of antigen available for uptake in the gut.

### EXAMPLES

#### 5 Example 1

Provided below are examples of typical assays used to monitor some acute phase inflammatory markers, as well as the ovarian cancer marker CA125.

##### *C-Reactive Protein*

10 C-Reactive Protein was measured using a DADE Behring Dimension RxL Chemistry Analyser, with reagents and calibrators supplied by Dade Behring Diagnostics (Sydney, Australia) (reagent-Cat No. DF-34; calibrators Cat. No. DC-34).

The CRP method is based on a particle enhanced turbidimetric immunoassay technique. Latex particles coated with antibody to C-Reactive Protein aggregate in the  
15 presence of C-Reactive Protein in the sample. The increase in turbidity which accompanies aggregation is proportional to the C-Reactive Protein concentration.

	INTRA-ASSAY PRECISION			INTER-ASSAY PRECISION		
20	MEAN mg/L	CV	N	MEAN mg/L	CV	N
	3.4	4.3%	20	4.6	5.6%	64
25	57.5	2.3%	20	37.0	3.0%	64
	225.8	2.0%	20			

REFERENCE RANGE: 0 – 5 mg/L

30 ANALYTICAL RANGE: 0.5 – 500 mg/L

##### *Cancer Antigen 125 (CA125)*

AxSym CA 125 was based on Microparticle Enzyme Immunoassay (MEIA) technology carried out on an Abbott Diagnostics AxSym with reagents and calibrators  
35 supplied by Abbott Diagnostics (AxSym Reagent pack-Cat No. 3B41-22; calibrators-Cat No. 9C22-01).

Sample, Anti CA 125 coated microparticles and specimen diluent are pipetted in one well of the reaction vessel. The CA 125 binds to the Anti-CA 125 coated microparticles forming an Ab-Ag complex. An aliquot of the reaction mixture containing the Ab-Ag complex bound to the microparticles bind irreversibly to the 5 glass fiber matrix. The matrix cell is washed with the wash buffer to remove the unbound materials. The anti-CA 125 subunit specific ALP conjugate is dispersed onto the matrix cell and binds with the Ab-Ag complex. The matrix cell is washed to remove unbound material. The substrate, 4-methyl umbelliferyl phosphate, is added to the matrix cell and the fluorescent product is measured by the MEIA optical assembly.

10 Dilutions are made with Abbott CA 125 specimen diluent (No. 3B41-50).

The coefficient of Variation as assessed from routine quality control sera at two levels (Abbott Tumour Marker Control (9C22-10 levels 1, 2 & 3) is as follows:

		MEAN	SD	CV %	N
15	LEVEL 1 U/mL	27	2.5	9.4	64
	LEVEL 2 U/mL	78	5.5	7.1	64
	LEVEL 3 U/mL	211	21.4	10.2	54

20 REFERENCE RANGES: 0 –35 U/mL

ANALYTICAL RANGE: 2 – 600 U/mL

#### *Interleukin 2 Receptor (IL2R)*

The receptor of the cytokine interleukin 2 (IL2R) was measured by a 25 commercial automated chemiluminescent Enzyme Immuno Assay (EIA) using an Immulite Analyser from Diagnostic Products Corporation (Los Angeles, CA, USA).

This is a competitive immunoassay using Alkaline Phosphatase labelled IL2R as tracer and adamantyl dioxetane as luminescent substrate for ALP enzyme.

All reagents and calibrators are supplied in kit form by DPC – Cat No. LKIPZ.

30 Analytical performance:

	MEAN	SD	CV %
	213 U/mL	13	6.1
	752 U/mL	49	6.5
35 LEVEL 3	2463 U/mL	189	7.7

ANALYTICAL RANGE: 5 – 7,500 U/mL

REFERENCE RANGE: 223 – 710 U/mL\*

\*Study performed on 87 apparently healthy adults.

*5 Interleukin 6*

The cytokine interleukin 6 was measured by a commercial automated chemiluminescent Enzyme Immuno Assay (EIA) using an Immulite Analyser from Diagnostic Products Corporation (Los Angeles, CA, USA).

This is a competitive immunoassay using Alkaline Phosphatase labelled IL-6 as tracer and adamantyl dioxetane as luminescent substrate for ALP enzyme.

All reagents and calibrators are supplied in kit form by DPC – Cat No. LK6PZ.

Analytical performance:

	MEAN	SD	CV %
15 LEVEL 1	88 pg/mL	4.5	5.1
LEVEL 2	230 pg/mL	12.2	5.3
LEVEL 3	638 pg/mL	46.6	7.3

ANALYTICAL RANGE: 2– 1000 pg/mL

20 REFERENCE RANGE: < 4.1 pg/mL\*

\*Study performed on 60 apparently healthy laboratory volunteers.

*Interleukin 10*

The cytokine interleukin 10 was measured by a commercial automated chemiluminescent Enzyme Immuno Assay (EIA) using an Immulite Analyser from Diagnostic Products Corporation, Los Angeles, Ca USA.

This is a competitive immunoassay using Alkaline Phosphatase labelled IL-10 as tracer and adamantyl dioxetane as luminescent substrate for ALP enzyme.

All reagents and calibrators are supplied in kit form by DPC – Cat No. LKXPZ.

30 Analytical performance:

	MEAN	SD	CV %
LEVEL 1	18.2 pg/mL	1.8	9.9
LEVEL 2	46.0 pg/mL	2.2	4.8
35 LEVEL 3	177 pg/mL	8.0	4.5

ANALYTICAL RANGE: 5 – 1000 pg/mL

REFERENCE RANGE: < 9.1 pg/mL\*

\*Study performed on 55 apparently healthy adults.

5 *Serum Amyloid A*

Polystyrene particles coated with antibodies to human SAA are agglutinated when mixed with samples containing SAA. The intensity of the scattered light in the nephelometer depends on the concentration of the analyte in the sample and consequently its concentration can be determined by comparison with dilutions of a standard of known concentration.

IMPRECISION: CV 4.7% @ 192 mg/L N=404  
CV 2.8% @ 7.0 mg/L N=40

15 REFERENCE RANGE: In a population with normal serum CRP levels (95<sup>th</sup> percentile = 5.0 mg/L N=483) the 95<sup>th</sup> percentile for N Latex SAA was found to be at 6.4 mg/L  
ANALYTICAL RANGE: 3.0 – 200 mg/L

*Complement C3*

20 The automated method used to measure complement C3 concentration in serum samples by nephelometric analysis using a Dade Behring ProSpect analyzer with reagents and calibrators supplied by Dade Behring Diagnostics (Sydney, Australia).

25 Soluble antigen solution (sample) and specific antibodies (antisera Cat No. OSAP15) are mixed in the reaction cuvettes. Insoluble antigen – antibody complexes form immediately, producing turbidity in the mixture and increasing the amount of light scattered by the solution. Following an incubation period the absorbance of the solution is measured at the analytical wavelength.

IMPRECISION: CV 5.5% @ 1.05 g/L N=61  
30 CV 3.2% @ 2.70 g/L N=61

REFERENCE RANGE: 0.81 – 1.85 g/L

ANALYTICAL RANGE: 0.10 – 3.50 g/L

*Complement C4*

The automated method used to measure complement C4 concentration in serum samples by nephelometric analysis using a Dade Behring ProSpect analyzer with reagents and calibrators supplied by Dade Behring Diagnostics (Sydney, Australia).

5 Soluble antigen solution (sample) and specific antibodies (antisera Cat No. OSAO15) are mixed in the reaction cuvettes. Insoluble antigen – antibody complexes form immediately, producing turbidity in the mixture and increasing the amount of light scattered by the solution. Following an incubation period the absorbance of the solution is measured at the analytical wavelength.

10

IMPRECISION:	CV 4.7% @ 0.20 g/L	N=61
	CV 3.8% @ 0.53 g/L	N=61

REFERENCE RANGE: 0.10 – 0.40 g/L

15 ANALYTICAL RANGE: 0.03 – 1.50 g/L

Example 2

An elderly female ovarian cancer patient was monitored for about 12 days for fluctuations in the levels of c-reactive protein, serum amyloid A and the tumour marker CA125. Monitoring was performed using standard laboratory tests on blood samples collected every other day. The patient had not recently been exposed to any anti-cancer therapy. Furthermore, there was no evidence that the patient was suffering from any diseases other than cancer. The CA125 (an ovarian cancer marker) was monitored as an indicator of disease burden.

25 As shown in Figure 1A, c-reactive protein (CRP) levels peaked at the beginning of the monitoring period. Furthermore, as shown in Figure 1B serum amyloid A levels were elevated at the same time of the CRP peak.

These results indicate that;

i) the levels of acute phase inflammatory proteins are fluctuating in a cancer patient in the absence of any other known factors which might cause these fluctuations such as viral infection or chemotherapy,

ii) elevated levels of acute phase inflammatory proteins was associated with lower levels of tumour antigens suggesting the presence of effector cells, and

iii) increased levels of tumour antigen is associated with lower levels of acute phase inflammatory proteins suggesting that regulator cells have counteracted the

35

beneficial activity of the effector cells such that these cells are no longer active against the tumour cells.

Example 3

5 A human subject suffering from a HIV infection was subjected to highly active antiretroviral therapy (HAART) for at least 6 months and then taken off the treatment. C-reactive protein levels were determined using standard techniques on samples obtained during and after the completion of HAART.

As can be seen in Figure 2, the results show that upon conclusion of HAART c-  
10 reactive protein levels began to cycle, peaking approximately every 14 days.

Example 4

Serum CRP was used to monitor the immune response in HIV patient who had stopped their anti-retroviral therapy (Figure 3). In this study CRP levels mimicked  
15 viral load fluctuations as the immune response switched on and off (Figure 3). It is interesting to note that these CRP fluctuations have an approximate 14 day cycle.

Example 5

The "Pubmed" database (<http://www.ncbi.nlm.nih.gov/>) was searched for the  
20 abstracts of journal articles which described the results of Phase II or Phase III clinical trials using anti-cancer agents (such as vinblastine and taxol) for the treatment of cancer. Other criteria that were used to select the "abstracts" were that the cancer was at a late stage (stage III or stage IV) and the disease had disseminated. Some studies used a single drug whereas others used combinations. No other criteria were used and  
25 studies with an atypical complete response rate were not disregarded.

The complete response rate (as indicated in the abstracts) for each trial was used to determine the average complete response rate of each type of cancer. The results are provided as Table 1. Notably, the average complete response rate varied only a small degree, namely between 5.1 to 8.2% for all cancers analysed. The results provided in  
30 Table 1 were used to determine the overall average complete response rate. This average complete response rate was 6.6% over at least 10 different types of cancers when considering the 144 trials analysed.

With specific regard to the data provided for ovarian cancer it should be noted that one study (Adachi et al., 2001) observed a complete response rate of 25% which  
35 was very large compared to the other 143 trials. This study looked at eight patients, with two patients providing a complete response rate. Whilst this is well within the

realms of possibility, if the study is ignored the overall complete response rate for the remaining ovarian cancer studies is 7.1%.

The complete response rates are remarkably consistent between the different cancers, and treatment regimes thereof, suggesting an underlying factor relevant to all 5 cancers and treatments thereof. As described herein, this factor is that the immune system is cycling. Accordingly, it can be argued that the complete response rates provided in Table 1 are the result of the anti-cancer agent being administered at an appropriate time such that effector cell numbers are maximized whilst regulator cell numbers are reduced or removed, or activity is down-regulated or compromised, by the 10 anti-cancer agent sufficient to elicit a complete response.

*Table 1 - Complete Response Rates Resulting from Clinical Trials with Anti-Cancer Drugs against Various Cancers.*

Cancer Type	Complete Response Rate (%)	Number of Trials
Mesothelioma <sup>a</sup>	5.1	10
Gastric <sup>b</sup>	7.33	15
Hepatocellular <sup>c</sup>	6.6	8
Pancreatic <sup>d</sup>	7.35	4
Melanoma <sup>e</sup>	7.5	15
Prostate <sup>f</sup>	5.15	7
NSC Lung <sup>g</sup>	5.85	6
Breast <sup>h</sup>	7.36	19
Ovarian <sup>i</sup>	8.2	15
Colorectal <sup>j</sup>	6.85	28
Miscellaneous <sup>k</sup>	6.0	17

15 <sup>a</sup> Tsavaris *et al* (1997), Monnet *et al* (2002), Pinto *et al* (2001), Kindler *et al* (1999), Yogelzang *et al* (1997), Planting *et al* (1995), Chahinian *et al* (1993), Raghavan *et al* (1990), Henss *et al* (1988) and Mbidde *et al* (1986).

16 <sup>b</sup> Kollmannsberger *et al* (2000), Sugimachi *et al* (2000), Jeen *et al* (2001), Yamada *et al* (2001), Aitini *et al* (2001), Cho *et al* (2002), Kornek *et al* (2002), Hofheinz *et al* (2002), Constenla *et al* (2002), Kim *et al* (2002), Louvet *et al* (2002), Kikuyama *et al* (2002), Bar Sela *et al* (2002), Murad *et al* (1999) and Sakata *et al* (1998).

20 <sup>c</sup> Porta *et al* (1995), Pohl *et al* (2001), Oon *et al* (1980), Choi *et al* (1984), Zeng *et al* (1998), Carr *et al* (1997), Patt *et al* (2003) and Leung *et al* (1999).

25 <sup>d</sup> Murad *et al* (2003), Ashamalla *et al* (2003), Safran *et al* (2002) and Sherman *et al* (2001).

<sup>e</sup> Retsas *et al* (1996), Nathan *et al* (2000), Bafaloukos *et al* (2002), Bafaloukos *et al* (2002), Buzaid *et al* (1998), Gibbs *et al* (2000), Atkins *et al* (2002), Gundersen *et al* (1989), Johnson *et al* (1985), Nystrom *et al* (2003), Einzig *et al* (1991), Bedikian *et al* (1995), Einzig *et al* (1996), Nathan *et al* (2000) and Chapman *et al* (2002).

30 <sup>f</sup> Hudes *et al* (1997), Kelly *et al* (2001), Savarese *et al* (1999), Small *et al* (2001), Savarese *et al* (2001), Trivedi *et al* (2000) and Picus *et al* (1999).

<sup>g</sup> Mariotta *et al* (2002), Recchia *et al* (2002), Perng *et al* (2000), Ginopoulos *et al* (1999), Paccagnella *et al* (1996) and Agelaki *et al* (2001).

<sup>h</sup> Freyer *et al* (2003), Morabito *et al* (2003), Kosmas *et al* (2003), Gebbia *et al* (2003), Thomas *et al* (1994), Romero *et al* (1994), Pectasides *et al* (2001), Frasci *et al* (2002),

5 Stathopoulos *et al* (2002), Gomez-Bernal *et al* (2003), Freyer *et al* (2003), Kornek *et al* (1998), Michelotti *et al* (1996), Kakolyris *et al* (1999), Twelves *et al* (1994), Fumoleau *et al* (1993) and Ibrahim *et al* (1999).

<sup>i</sup> Li *et al* (2002), Sehouli *et al* (2002), Rose *et al* (2003), Fairve *et al* (2002), Dieras *et al* (2002), Adachi *et al* (2001), Sutton *et al* (1994), McClay *et al* (1995), Manetta *et al*

10 (1994), Guastalla *et al* (1994), Covens *et al* (1992), Einzig AI. (1994), Kjorstad *et al* (1992), Ozols *et al* (1984), Planner *et al* (1996) and Amadori *et al* (1997).

<sup>j</sup> Cassinello *et al* (2003), Glimelius *et al* (2002), Calvo *et al* (2002), Scheithauer *et al* (2002), Neri *et al* (2002), Falcone *et al* (2001), Kouroussis *et al* (2001), Meropol *et al* (2001), Comella *et al* (2000), Cascinu *et al* (1999), Sobrero *et al* (1995), Gamelin *et al*

15 (1998), Romero *et al* (1998), Beerblock *et al* (1997), Blanke *et al* (1997), Grem *et al* (1993), Jeremic *et al* (1993), Posner *et al* (1992), Sinnige *et al* (1990), LoRusso *et al* (1989), Petrelli *et al* (1989), Valdivieso *et al* (1981), Cassinello *et al* (2003), Reina *et al* (2003), Comella *et al* (1999), Neri *et al* (1998), Pyrhonen *et al* (1992) and Beck *et al* (1984).

20 <sup>k</sup> Cancers included renal cell carcinoma, adenocarcinoma, squamous cell carcinoma, uterine cervical cancer, glioblastoma multiforme, metastatic osteosarcoma, urothelial cancer and endometrial cancer. Described by Schornagel *et al* (1989), Liu *et al* (2001), Forastiere *et al* (1987), Okuno *et al* (2002), Takasugi *et al* (1984), Hurteloup *et al* (1986), Kakolyris *et al* (2002), Morris *et al* (1998), Takeuchi *et al* (1991), Fountzilas *et al* (1999), Rosenthal *et al* (2000), Goorin *et al* (2002), Rodriguez-Galindo *et al* (2002), Ahmad *et al* (2002), DiPaola *et al* (2003) and Lissoni *et al* (1996).

If the typical cycle of effector/regulator cell numbers is considered as about 15 days, the data in Table 1 suggest a one day window to administer the anti-cancer therapy to achieve a complete response rate. Partial response rates in the order of 30% are typically noted suggesting that if the agent is administered at a 24 to 36 hour period either side of this "one day window" a beneficial effect can also be achieved.

#### Example 6

##### *35 Patient*

The patient was a 75 year old female designated herein "Mrs OM".

##### *History*

Liver cirrhosis, ischaemic heart disease, insulin dependent diabetic. Diagnosed 40 with squamous cell carcinoma of lower oesophagus by endoscopy and biopsy/histology May 2004. The cancer resulted in the patient finding it difficult to swallow.

*Tumour Description*

Five centimetre circumferential mass at the base of the oesophagus, partially occluding the lumen. Unknown epithelial/mural penetration.

**5 Therapy Regimen**

Radiotherapy approx 33 courses of 15 minutes duration every week day over 6-8 weeks. Plus limited chemotherapy due to underlying other medical conditions.

The oncologist agreed to give two application of chemotherapy (~8hr infusion of 5 Fluorouracil and Carboplatin). The application would be coordinated with the 10 patient's immune response cycle/oscillation to attempt timed down-regulation of cycling tumour specific regulator cells.

*Monitoring and Therapeutic Intervention*

To detect the immune response oscillation, monitoring of the patient's immune 15 response started on the 28/5/2004, day 1, using the following assays; CRP, SAA, C3, C4 & CA125. CA125 was used to monitor disease progression as this has been reported in the literature in the case of squamous cell carcinoma of the oesophagus.

During the initial stages of monitoring, the patient reported increased difficulty 20 in swallowing, most likely due to the tumour growing. This was corroborated by a consistent rise in all the measured parameters (see Figures 4 to 7).

Interestingly the climbing CA125 briefly plateaued over an approximate 24hr period, (Figure 6 day 12-14) only to rise at a steeper gradient beyond that point. This was interpreted as the patient's immune response switching on and modulating the tumour growth and marker (CA125), only to switch off due to immune regulation at the 25 end of the approximate 24hr period.

This approximate 24hr period established the end of one about 14 day cycle and the beginning of the next, and therefore a potential intervention point or a reference point for projecting ahead to further intervention points.

Having defined the beginning and end of the ~14 day cycle it was now possible 30 to anticipate and project forward a number of days to best estimate two potential chemotherapeutic intervention points approximately 2 weeks apart.

It was decided to take blood/measurements from the patient on the Tuesday, Wednesday and Thursday (Figure 7, 13,14 & 15 July, days 46,47 & 48, arrowed as B) to accurately define the therapeutic intervention point or window. If the cycle had been 35 accurately determined, a peak followed by a down turn in the CRP should be seen over those days on which analysis was carried out. (Figure 7). This pattern in the CRP

should be repeated approximately 14 days later and in keeping with the persistent periodicity of the immune response oscillation. This was found to be the case (Figure 7).

Based on the CRP results, the inventor recommended to the oncologist to 5 administer the first application of chemotherapy about Wednesday 14/7/2004 or Thursday 15/7/2004. However, Mrs OM had already been booked for chemotherapy on Friday 16/7/2004, and the oncologist decided not to change this appointment. Since this date was just after the peak in the CRP (Figure 7, arrowed as C) it was felt by the inventor that the window of opportunity may have been missed because the application 10 of therapy may be 24hrs too late. The inventor expected that at the time the therapy was administered CRP would have begun to rise again. This prediction proved correct as no effect was apparent on the tumour after administration of the chemotherapy.

A second intervention point was determined/predicted and blood was taken on the Wednesday and Thursday (Figure 7, 28<sup>th</sup> & 29<sup>th</sup> July, days 63 and 64 arrowed as 15 D). The prediction was confirmed by a peak in the CRP analysis indicating Friday 30/7/2004, day 65 (Figure 7, arrowed as E) as the optimal intervention point for application of chemotherapy. Chemotherapy was administered as an 8 hr infusion on the Friday. On this occasion the inventor predicted that this would be appropriate time to administer the therapy as the CRP would still be decreasing.

20 On the Saturday the patient developed a mild fever and felt generally unwell. Early afternoon on the Sunday 1<sup>st</sup> August, day 67, (Figure 7, arrowed as F), the patient haemorrhaged from the tumour site and consequently was admitted to hospital. The patient lost about 150mls of blood and received 2 units of blood that day and intravenous fluids/nourishment for the next 9 days.

25 CRP was measured on 4/8/2004, day 69 (Figure 7, arrowed as G), and was found to have dropped significantly.

On the last day of hospitalisation the patient's oesophagus was examined endoscopically. No tumour was evident (Figure 7, arrowed as H).

### 30 *Interpretation*

The patient's oscillating antitumour immune response was released from regulation by the timed targeting of tumour specific regulator cells by the single administration of the chemotherapeutic agents at the right designated time. This is when immune regulatory cells are clonally active, in mitosis and thus vulnerable to 35 down-regulation. Once released from regulation the anti-tumour immune response resulted in a febrile episode as reported by the patient on day 66 and subsequent tumour

destruction. The immune mediated tumour destruction resulted in haemorrhage due to the tumour's potential invasive involvement in the epithelium / wall of the oesophagus.

The above actions and observations demonstrates the following:

- It is possible to detect a persistent regular oscillation in the cancer patient.
- 5     • This oscillation is associated with the tumour burden.
- The oscillation has an approximate 14 day periodicity with a 7 day sub cycle.
- The beginning and end of the cycle can be determined by different parameters such as but not limited to CRP, SAA, C3, C4 and tumour antigen levels.
- The narrow window of opportunity for the application of a single.
- 10    • administration of chemotherapy can be determined.
- A single chemotherapeutic administration at the correct time directed against the cancer patient's immune system can lead to a successful therapeutic outcome.

#### Example 7

15       The patient was a 71 year old female designated herein "Mrs FO". Previously Mrs FO was diagnosed with ovarian cancer, received surgery and several rounds of standard chemotherapy. Patient represented with elevated CA125 at 200U/ml prior to monitoring.

Patient was monitored (bled) every Monday, Wednesday & Friday for 4 weeks.  
20      A well described near synchronous and regular oscillation with a 7 /14 day periodicity showing a close correlation between CRP, SAA & IL-2 serum measurements (see Figures 8 and 9). More interestingly, Figure 10 which shows CRP & CA125 versus time, the CRP and CA125 oscillations are out of phase, indicating an inverse relationship between the immune system and the cancer marker.

25      Figure 11 shows the relationship over time between SAA and complement factor C3. Note that the two major C3 peaks are approximately 14 days apart and coincide with alternating SAA peaks which are also approximately 14 days apart. This supports a hypothesis that the 7 day peaks represent alternating T and B cell clonal expansions and the major C3 peaks are B cell associated as complement is associated  
30    with antibody mediated lysis. This observation can assist in establishing the beginning and end of a cycle and therefore can also assist in determining the therapeutic intervention point.

#### Example 8

35       The patient was a 64 year old male designated herein "Mr GA". Bowel cancer was first diagnosed 1997, following which the patient was exposed to surgery,

chemotherapy and radiotherapy. Lung recurrence was diagnosed by needle biopsy in February 2004. The patient was determined to possess multiple lesions and was subjected to 12 rounds of chemotherapy. The last chemotherapy was in September 2004. The most recent scan identified at least one 2 cm lesion upper left lung.

5 Currently, relatively well/active (mid October 2004).

Blood was taken every other day (Monday, Wednesday, Friday) for 15 days. CRP was measured, with the resulting showing an approximate and regular 7/14 day CRP oscillation.

10 Example 9

A post menopausal oopherectomised patient (WB) with re-emerging tumour and elevated CA125 levels was asked to record the frequency of hot flushes or febrile episodes and grade them as mild, moderate or severe. The intensity of these episodes were matched to the immune response CRP oscillation. The more intense episodes and 15 their increased frequency were coincident with the large peaks. Thus recording body temperature may be used as an adjunct to define the beginning and or end of the immune response oscillation for the purposes of timing the application of therapy.

20 Cross-Reference to Related Applications

The present application claims priority from Provisional Patent Application No 2003905858 filed on 24 October 2003, the contents of which is incorporated herein by reference.

25 It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

30 All publications discussed above are incorporated herein in their entirety.

Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the 35 field relevant to the present invention as it existed before the priority date of each claim of this application.

**REFERENCES**

Adachi, S., Ogasawara, T., Ito, K., Koyama, M., *et al* (2001) Oncol. Rep. 8:285-288.

5 5 Agelaki, S., Bania, H., Kouroussis, C., Blazoyiannakis, G., *et al* (2001) Lung Cancer 4:S77-80.

Ahmad, S.A., Patel, S.R., Ballo, M.T., Baker, T.P., *et al* (2002) J. Clin. Oncol. 20:521-527.

10 10 Aitini, E., Rabbi, C., Mambrini, A., Cavazzini, G., *et al* (2001) Tumori 87:20-24.

Amadori, D., Sansoni, E. and Amadori, A. (1997) Frontiers in Bioscience 2:20-26.

15 15 Ashamalla, H., Zaki, B., Mokhtar, B., Colella, F., *et al* (2003) Int. J. Radiat. Oncol. Biol. Phys. 55:679-687.

Atkins, M.B., Gollob, J.A., Sosman, J.A., McDermott, D.F., *et al* (2002) Clin. Cancer Res. 8:3075-3081.

20 20 Aziz, M., Akhtar, S. and Malik, A. (1998) Cancer Detect. Prev. 22:87-99.

Bafaloukos, D., Aravantinos, G., Fountzilas, G., Stathopoulos, G., *et al* (2002) Oncology 63:333-337.

25 25 Bafaloukos, D., Gogas, H., Georgoulias, V., Briassoulis, E., *et al* (2002) J. Clin. Oncol. 20:420-425.

Bar Sela, G., Tsalic, M., Gaitini, D., Steiner, M., *et al* (2002) J. Chemother. 14:623-626.

30 30 Beck, T.M., Curtis, P.W., Woodard, D.A., Hart, N.E., *et al* (1984) Cancer Treat. Rep. 68:647-650.

Bedikian, A.Y., Weiss, G.R., Legha, S.S., Burris, H.A., *et al* (1995) J. Clin. Oncol. 13:2895-2899.

Beerblock, K., Rinaldi, Y., Andre, T., Louvet, C., *et al* (1997) Cancer 79:1100-1105.

40 Belli F, Testori A, Rivoltini L, Maio M, *et al*. (2002) J Clin Oncol. 20:4169-4180.

Berd D, Sato T, Cohn H, Maguire HC Jr, Mastrangelo MJ. (2001) Int J Cancer. 94:531-539.

45 Blanke, C.D., Kasimis, B., Schein, P., Capizzi, R., *et al* (1997) J. Clin. Oncol. 15:915-920.

Buzaid, A.C., Colome, M., Bedikian, A., Eton, O., *et al* (1998) Melanoma Res. 8:549-556.

5 Calvo, E., Cortes, J., Rodriguez, J., Fernandez-Hidalgo, O., *et al* (2002) Clin. Colorectal Cancer 2:104-110.

Carr, B.I., Zajko, A., Bron, K., Orons, P., *et al* (1997) Semin. Oncol. 24:S6-97-S6-99.

10 Cascinu, S., Silva, R.R., Labianca, R., Barni, S., *et al* (1999) Ann. Oncol. 10:985-987.

Cassinello, J., Escudero, P., Salud, A., Marcos, F., *et al* (2003) Clin. Colorectal Cancer 3:108-112.

15 Cassinello, J., Lopez-Alvarez, P., Martinez-Guisado, A., Valladares, M., *et al* (2003) Med. Oncol. 20:37-43.

Chahinian, A.P., Antman, K., Goutsou, M., Corson, J.M., *et al* (1993) J. Clin. Oncol. 11:1559-1165.

20 Chapman, P.B., Panageas, K.S., Williams, L., Wolchok, J.D., *et al* (2002) Melanoma Res. 12:381-387.

Cho, E.K., Lee, W.K., Lim do, Y., Bang, S.M., *et al* (2002) J. Korean Med. Sci. 17:348-352.

25 Choi, T.K., Lee, N.W. and Wong, J. (1984) Cancer 53:401-405.

Comella, P., De Vita, F., Mancarella, S., De Lucia, L., *et al* (2000) Ann. Oncol. 11:1323-1333.

30 Comella, P., Lorusso, V., Casaretti, R., De Lucia, L., *et al* (1999) Tumori. 85:465-472.

Constenla, M., Garcia-Arroyo, R., Lorenzo, I., Carrete, N., *et al* (2002) Gastric Cancer 5:142-147.

35 Covens, A., O'Connell, G., Rusthoven, J. and Mazurka, J. (1992) Eur. J. Gynaecol. Oncol. 13:125-130.

40 Dieras, V., Bougnoux, P., Petit, T., Chollet, P., *et al* (2002) Ann. Oncol. 13:258-266.

DiPaola, R.S., Rubin, E., Toppmeyer, D., Eid, J., *et al* (2003) Med. Sci. Monit. 9:P15-11.

45 Eda, S., Kaufmann, J., Roos, W. and Phol, S. (1998) J. Clin. Lab. Analysis 12:137-144.

Einzig, A.I. (1994) Ann. Oncol. 6:S29-32.

Einzig, A.I., Hochster, H., Wiernik, P.H., Trump, D.L., *et al* (1991) Invest New Drugs 9:59-64.

5 Einzig, A.I., Schuchter, L.M., Recio, A., Coatsworth, S., *et al* (1996) Med. Oncol. 13:111-117.

Faivre, S., Le Chevalier, T., Monnerat, C., Lokiec, F., *et al* (2002) Ann. Oncol. 13:1479-1489.

10 Falcone, A., Allegrini, G., Masi, G., Lencioni, M., *et al* (2001) Oncology 61:28-35.

Forastiere, A.A., Gennis, M., Orringer, M.B. and Agha, F.P. (1987) J. Clin. Oncol. 5:1143-1149.

15 Fountzilas, G., Karavelis, A., Capizzello, A., Kalogera-Fountzila, A., *et al* (1999) J. Neurooncol. 45:159-165.

Frasci, G., D'Aiuto, G., Comella, P., Thomas, R., *et al* (2002) Oncology 62:25-32.

20 Freyer, G., Delozier, T., Lichinister, M., Gedouin, D., *et al* (2003) J. Clin. Oncol. 21:35-40.

Fumoleau, P., Delgado, F.M., Delozier, T., Monnier, A., *et al* (1993) J. Clin. Oncol. 11:1245-1252.

25 Gamelin, E., Boisdran-Celle, M., Delva, R., Regimbeau, C., *et al* (1998) J. Clin. Oncol. 16:1470-1478.

30 Gebbia, V., Blasi, L., Borsellino, N., Caruso, M., *et al* (2003) Anticancer Res. 23:765-771.

Gibbs, P., Iannucci, A., Becker, M., Allen, J., *et al* (2000) Melanoma Res. 10:171-179.

35 Ginopoulos, P., Mastronikolis, N.S., Giannios, J., Karana, A., *et al* (1999) Lung Cancer 23:31-37.

Glimelius, B., Ristamaki, R., Kjaer, M., Pfeiffer, P., *et al* (2002) Ann. Oncol. 13:1868-1873.

40 Gomez-Bernal, A., Cruz, J.J., Garcia-Palomo, A., Arizcun, A., *et al* (2003) Am. J. Clin. Oncol. 26:127-131.

Goorin, A.M., Harris, M.B., Bernstein, M., Ferguson, W., *et al* (2002) J. Clin. Oncol. 20:426-433.

45

Grem, J.L., Jordan, E., Robson, M.E., Binder, R.A., *et al* (1993) *J. Clin. Oncol.* 11:1737-1745.

Guastalla, J.P., Vermorken, J.B., Wils, J.A., George, M., *et al* (1994) *Eur. J. Cancer* 30A:45-49.

Gundersen, S. and Flokkmann, A. (1989) *Cancer* 64:1617-1619.

Henss, H., Fiebig, H.H., Schildge, J., Arnold, H., *et al* (1988) *Onkologie* 11:118-120.

10 Hofheinz, R.D., Hartung, G., Samel, S., Hochhaus, A., *et al* (2002) *Onkologie* 25:255-260.

Horvath, M., Fekete, B. and Rahoty, P. (1982) *Oncology* 39:20-22.

15 Hudes, G.R., Nathan, F., Khater, C., Haas, N., *et al* (1997) *J. Clin. Oncol.* 15:3156-3163.

Hurteloup, P., Armand, J.P., Cappelaere, P., Metz, R., *et al* (1986) *Cancer Treat. Rep.* 70:731-737.

20 Ibrahim, N.K., Rahman, Z., Valero, V., Willey, J., *et al* (1999) *Cancer* 86:1251-1257.

Jeen, Y.T., Yoon, S.Y., Shin, S.W., Kim, B.S., *et al* (2001) *Cancer* 91:2288-2293.

25 Jeremic, B., Acimovic, L. and Mijatovic, L. (1993) *Cancer* 71:2706-2708.

Johnson, D.H., Presant, C., Einhorn, L., Bartolucci, A.A., *et al* (1985) *Cancer Treat. Rep.* 69:821-824.

30 Kakolyris, S., Kourousis, C., Koukourakis, M., Androulakis, N., *et al* (1999) *Am. J. Clin. Oncol.* 22:568-572.

Kakolyris, S., Kouroussis, C., Koukourakis, M., Marvroudis, D., *et al* (2002) *Oncology* 63:213-218.

35 Kelly, W.K., Curley, T., Slovin, S., Heller, G., *et al* (2001) *J. Clin. Oncol.* 19:44-53.

Kikuyama, S., Inada, T., Oyama, R. and Ogata, Y. (2002) *Anticancer Res.* 22:3633-3636.

40 Kim, T.W., Kang, Y.K., Ahn, J.H., Chang, H.M., *et al* (2002) *Ann. Oncol.* 13:1893-1898.

Kimura, M., Tomita, Y., Imai, T., Saito, T. et al. (2001) *Cancer* 92:2072-2075.

Kindler, H.L., Belani, C.P., Herndon, J.E., Vogelzang, N.J., *et al* (1999) Cancer 86:1985-1991.

Kjorstad, K., Harris, A., Bertelsen, K., Slevin, M., *et al* (1992) Ann. Oncol. 3:217-222.

Kollmannsberger, C., Quietzsch, D., Haag, C., Lingenfelser, T., *et al* (2000) Br. J. Cancer 83:458-462.

Kornek, G.V., Haider, K., Kwasny, W., Lang, F., *et al* (1998) Br. J. Cancer 78:673-678.

Kornek, G.V., Raderer, M., Schull, B., Fiebiger, W., *et al* (2002) Br. J. Cancer 86:1858-1863.

Kosmas, C., Tsavaris, N., Malamos, N., Stavroyianni, N., *et al* (2003) Br. J. Cancer 88:1168-1174.

Kouroussis, C., Souglakos, J., Kakolyris, S., Mavroudis, D., *et al* (2001) Oncology 61:36-41.

Leung, T.W., Patt, Y.Z., Lau, W.Y., Ho, S.K., *et al* (1999) Clin. Cancer Res. 5:1676-1681.

Li, J.D., Guan, Z.Z., Liu, J.H., Xin, X.Y., *et al* (2002) Ai Zheng 21:416-420.

Lissoni, A., Zanetta, G., Losa, G., Gabriele, A., *et al* (1996) Ann. Oncol. 7:861-863.

Liu, J.H., Yang, M.H., Fan, F.S., Yen, C.C., *et al* (2001) Urology 57:650-654.

Liuzzo, G., Biasucci, L.M., Gallimore, J.R., Grillo, R.L. et al. (1994) New Engl. J. Med. 331:417-424.

LoRusso, P., Pazdur, R., Redman, B.G., Kinzie, J., *et al* (1989) Am. J. Clin. Oncol. 12:486-490.

Lotem M, Shiloni E, Pappo I, Drize O, *et al*. (2004) Br J Cancer 90:773-780.

Louvet, C., Andre, T., Tigaud, J.M., Gamelin, E., *et al* (2002) J. Clin. Oncol. 20:4543-4548.

Manetta, A., Boyle, J., Berman, M.L., DiSaia, P.J., *et al* (1994) Cancer 73:196-199.

Mariotta, S., Sposato, B., Li Bianchi, E., Fiorucci, F., *et al* (2002) Eur. Rev. Med. Pharmacol. Sci. 6:49-54.

Mbidde, E.K., Harland, S.J., Calvert, A.H. and Smith, I.E. (1986) Cancer Chemother. Pharmacol. 18:284-285.

McClay, E.F., Braly, P.D., Kirmani, S., Plaxe, S.C., *et al* (1995) Am. J. Clin. Oncol. 5 18:23-26.

Meropol, N.J., Niedzwiecki, D., Hollis, D., Schilsky, R.L., *et al* (2001) Cancer 91:1256-1263.

Michelotti, A., Gennari, A., Salvadori, B., Giannessi, P.G., *et al* (1996) Semin. Oncol. 10 23:38-40.

Monnet, I., Breau, J.L., Moro, D., Lena, H., *et al* (2002) Chest 121:1921-1927.

Morabito, A., Filippelli, G., Palmeri, S., Cascinu, S., *et al* (2003) Breast Cancer Res. 15 Treat. 78:29-36.

Morris, M., Brader, K.R., Levenback, C., Burke, T.W., *et al* (1998) J. Clin. Oncol. 16:1094-1098.

20 Murad, A.M., Guimaraes, R.C., Aragao, B.C., Rodrigues, V.H., *et al* (2003) Am. J. Clin. Oncol. 26:151-154.

Murad, A.M., Petriano, A., Guimaraes, R.C., Aragao, B.C., *et al* (1999) Am. J. Clin. Oncol. 22:580-586.

25 Nathan, F.E., Berd, D., Sato, T. and Mastrangelo, M.J. (2000) Cancer 88:79-87.

Neri, B., Doni, L., Fulignati, C., Perfetto, F., *et al* (2002) Anticancer Drugs 13:719-724.

30 Neri, B., Gemelli, M.T., Pantalone, D., Pernice, M.L., *et al* (1998) Anticancer Drugs 9:599-602.

North, R. J. and Awwad, M. (1990) Immunology 71:90-95.

35 Nystrom, M.L., Steele, J.P., Shamash, J., Neville, F., *et al* (2003) Melanoma Res. 13:197-199.

O'Hanlon, D.M., Lynch, J., Cormican, M. and Given, H.F. (2002) Anticancer Res. 22:1289-1294.

40 O'Hara, R., Murphy, E.P., Whitehead, A.S., Fitzgearld, O. and Bresnihan, B. (2000) Arthritis Research 2:142-144.

Okuno, S.H., Mailliard, J.A., Suman, V.J., Edmonson, J.H., *et al* (2002) Cancer 45 94:2224-2231.

Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., *et al* (1999) Cancer Res. 59:3128-3133.

5 Oon, C.J., Chua, E.J., Foong, W.C., Tan, L.K., *et al* (1980) Ann. Acad. Med. Singapore 9:256-259.

Ozols, R.F., Speyer, J.L., Jenkins, J. and Myers, C.E. (1984) Cancer Treat. Rep. 68:1229-1232.

10 Paccagnella, A., Favaretto, A., Oniga, F., Festi, G., *et al* (1996) Cancer 78:1701-1707.

Patt, Y.Z., Hassan, M.M., Lozano, R.D., Brown, T.D., *et al* (2003) J. Clin. Oncol. 21:421-427.

15 Pectasides, D., Dimopoulos, M.A., Aravantinos, G., Kalophonos, H.P., *et al* (2001) Anticancer Res. 21:3575-3580.

Perng, R.P., Shih, J.F., Chen, Y.M., Delgado, F.M., *et al* (2000) Am. J. Clin. Oncol. 23:60-64.

Peterson, K.E., Strommes, I., Messer, R., Hasenkrug, K. and Chesebro, B. (2002) J. Viriol. 76:7942-7948.

25 Petrelli, N.J., Madejewicz, S., Rustum, Y., Herrera, L., *et al* (1989) Cancer Chemother. Pharmacol. 23:57-60.

Picus, J. and Schultz, M. (1999) Semin. Oncol. 26:14-18.

30 Pinto, C., Marino, A., Guaraldi, M., Melotti, B., *et al* (2001) Am. J. Clin. Oncol. 24:143-147.

Planner, R.S., Allen, D.G., Brand, A.H., Grant, P.T., *et al* (1996) Aust N.Z. J. Obstet. Gynaecol. 36:168-170.

35 Planting, A.S., van der Burg, M.E., Goey, S.H., Schellens, J.H., *et al* (1995) Ann. Oncol. 6:613-615.

Pohl, J., Zuna, I., Stremmel, W. and Rudi, J. (2001) Chemotherapy 47:359-365.

40 Porta, C., Moroni, M., Nastasi, G. and Arcangeli, G. (1995) Oncology 52:487-491.

Posner, M., Martin, A., Slapak, C.A., Clark, J.W., *et al* (1992) Am. J. Clin. Oncol. 15:239-241.

45

Price, C.P., Trull, A.K., Berry, D. and Gorman, E.G. (1987) J. Immunol. Methods 99:205-211.

Pyrhonen, S.O. and Kouri, M.O. (1992) Eur. J. Cancer 28A:1828-1832.

5 Raghavan, D., Gianoutsos, P., Bishop, J., Lee, J., *et al* (1990) J. Clin. Oncol. 8:151-154.

Read, S., Malmstrom, V. and Powrie, F. (2000) J. Exp. Med. 192:295-302.

10 Recchia, F., Lombardo, M., De Filippis, S., Rosselli, M., *et al* (2002) Anticancer Res. 22:1321-1328.

15 Reina, J.J., Aparicio, J., Salvador, J., Pica, J.M., *et al* (2003 in press) Cancer Chemother. Pharmacol.

Retsas, S., Mohith, A. and Mackenzie, H. (1996) Anticancer Drugs 7:161-165.

20 Rodriguez-Galindo, C., Daw, N.C., Kaste, S.C., Meyer, W.H., *et al* (2002) J. Pediatr. Hematol. Oncol. 24:250-255.

Romero, A., Rabinovich, M.G., Vallejo, C.T., Perez, J.E., *et al* (1994) J. Clin. Oncol. 12:336-341.

25 Romero, A.O., Perez, J.E., Cuevas, M.A., Lacava, J.A., *et al* (1998) Am. J. Clin. Oncol. 21:94-98.

Rose, P.G., Blessing, J.A., Ball, H.G., Hoffman, J., *et al* (2003) Gynecol. Oncol. 88:130-135.

30 Rosenthal, M.A., Gruber, M.L., Glass, J., Nirenberg, A., *et al* (2000) J. Neurooncol. 47:59-63.

Safran, H., Dipetrillo, T., Iannitti, D., Quirk, D., *et al* (2002) Int. J. Radiat. Oncol. Biol. Phys. 54:137-141.

35 Sakata, Y., Ohtsu, A., Horikoshi, N., Sugimachi, K., *et al* (1998) Eur. J. Cancer 34:1715-1720.

40 Salomon, B., Lenschow, D. J., Rhee, L., Ashourian, N., *et al* (2000) Immunity 12:431-440.

Savarese, D., Taplin, M.E., Halabi, S., Hars, V., *et al* (1999) Semin. Oncol. 26:39-44.

45 Savarese, D.M., Halabi, S., Hars, V., Akerley, W.L., *et al* (2001) J. Clin. Oncol. 19:2509-2516.

Scheithauer, W., Kornek, G.V., Raderer, M., Schull, B., *et al* (2002) Ann. Oncol. 13:1583-1589.

5 Schornagel, J.H., Verweij, J., ten Bokkel Huinink, W.W., Klijn, J.G., *et al* (1989) J. Urol. 142:253-256.

Sehouli, J., Stengel, D., Oskay, G., Camara, O., *et al* (2002) Ann. Oncol. 13:1749-1755.

10 Senju, O., Takagi, Y., Gomi, K., Ishii, N., et al. (1983) Jap. J. Clin. Lab. Automation 8:161-165.

Sherman, W.H. and Fine, R.L. (2001) Oncology 60:316-321.

15 Shimizu, J., Yamazaki, S. and Sakaguchi, S. (1999) J. Immunol. 163:5211-5218.

Shimizu, J., Yamazaki, S., Takahashi, T., Ishida, Y. and Sakaguchi, S. (2002) Nature Immunol. 3:135-142.

20 Sinnige, H.A., Sleijfer, D.T., de Vries, E.G., Willemse, P.H., *et al* (1990) Eur. J. Cancer 26:625-628.

Small, E.J., Bok, R., Reese, D.M., Sudilovsky, D., *et al* (2001) Semin. Oncol. 28:71-76.

25 Smithers M, O'Connell K, MacFadyen S, Chambers M, *et al*. (2003) Cancer Immunol Immunother. 52:41-52.

Sobrero, A.F., Aschele, C., Guglielmi, A.P., Mori, A.M., *et al* (1995) Clin. Cancer Res. 30 1:955-960.

Stathopoulos, G.P., Rigatos, S.K., Pergantas, N., Tsavdarides, D., *et al* (2002) J. Clin. Oncol. 20:37-41.

35 Sugimachi, K. and Maehara, Y. (2000) Surg. Today 30:1067-1072.

Suri-Payer, E. and Cantor, H. (2001) J. Autoimmunity 16:115-23.

40 Sutmuller, R. P., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. *et al* (2001) J. Exp. Med. 194:823-832.

Sutton, G.P., Blessing, J.A., Homesley, H.D. and Malfetano, J.H. (1994) Gynecol. Oncol. 53:24-26.

Takahashi, T., Tagami, T., Yamazaki, S., Uede, T. *et al* (2000) *J. Exp. Med.* 192:303-310.

Takasugi, B.J., Robertone, A.B., Salmon, S.E., Jones, S.E., *et al* (1984) *Invest New Drugs* 2:387-390.

Takeuchi, S., Dobashi, K., Fujimoto, S., Tanaka, K., *et al* (1991) *Gan to Kagaku Ryoho* 18:1681-1689.

10 Thomas, G.W., Muss, H.B., Jackson, D.V., McCulloch, J., *et al* (1994) *Cancer Chemother. Pharmacol.* 35:165-168.

Trefzer U, Herberth G, Wohlan K, Milling A, *et al*. (2004) *Int J Cancer* 110:730-740.

15 Trivedi, C., Redman, B., Flaherty, L.E., Kucuk, O., *et al* (2000) *Cancer* 89:431-436.

Tsavaris, N., Primikirios, N., Mylonakis, N., Varouchakis, G., *et al* (1997) *Anticancer Res.* 17:3799-3802.

20 Twelves, C.J., Dobbs, N.A., Curnow, A., Coleman, R.E., *et al* (1994) *Br. J. Cancer* 70:990-993.

Valdivieso, M., Bedikian, A.Y., Bodey, G.P. and Freireich, E.J. (1981) *Cancer Treat. Rep.* 65:877-879.

25 Weinstein, P.S., Skinner, M., Sipe, J.D., Lokich, J.J. et al. (1984) *Scand. J. Immunol.* 19:193-198.

Wittig B, Marten A, Dorbic T, Weineck S, *et al*. (2001) *Hum Gene Ther.* 12:267-278.

30 Yamada, Y., Shirao, K., Ohtsu, A., Boku, N., *et al* (2001) *Ann. Oncol.* 12:1133-1137.

Yogelzang, N.J., Herndon, J.E., Cirrincione, C., Harmon, D.C., *et al* (1997) *Cancer* 79:2237-2242.

35 Zeng, Z.C., Tang, Z.Y., Liu, K.D., Lu, J.Z., *et al* (1998) *J. Cancer Res. Clin. Oncol.* 124:275-280.